Cardioprotective role of A-cycloglycosylated derivative of Rubiadin in diabetic cardiomyopathy in rats

• Published in: International immunopharmacology Vol. 118; p. 110008
• Main Authors: Zhu, Mo-li, Yu, Ya-nan, Song, Yu-ting, Wang, Can-yu, Miao, Zheng, Chen, Bu-lei, Guo, Shuang, Shen, Miao-miao, Zhang, Ming-xiang, Zhan, He-qin, Yang, Peng-fei, Wang, Qian-qian, Yin, Ya-lin, Li, Peng
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01-05-2023
• Subjects: ACDR; Animals; Anthraquinones - pharmacology; Diabetes Mellitus, Experimental - metabolism; Diabetic Cardiomyopathies - etiology; Diabetic cardiomyopathy; Hey1; Myocardium - metabolism; NHE1; Oxidative Stress; P38; Rats; Diabetic cardiomyopathy; Oxidative stress; NHE1; P38; ACDR; Hey1
• ISSN: 1567-5769; 1878-1705
• DOI: 10.1016/j.intimp.2023.110008

[Display omitted]
•A-cycloglycosylated derivative of Rubiadin protects cardiac function in rats with streptozotocin-induced diabetic cardiomyopathy.•A-cycloglycosylated derivative of Rubiadin inhibits NHE1 activation in the heart of rats with diabetic cardiomyopathy.•A-cycloglycosylated derivative of Rubiadin attenuates diabetic cardiomyopathy by ameliorating oxidative stress.
Diabetic cardiomyopathy (DCM) is a kind of idiopathic heart disease, which is one of the main complications of diabetes and seriously threatens the life of diabetic patients. Rubiadin, an anthraquinone compound extracted from the stems and roots of rubiaceae, has been widely discussed for its anti-diabetes, anti-oxidation and other pharmacological effects. However, Rubiadin can cause drug-induced liver injury. Therefore, A-cycloglycosylated derivative of Rubiadin (ACDR) was obtained by modifying its structure. The purpose of this study was to investigate the effect of ACDR on DCM cardiac injury and its mechanism. The DCM animal model was established by streptozotocin, and the success of DCM was verified by blood glucose level, echocardiographic evidence of impaired myocardial functions along with enhanced myocardial fibrosis. We performed liver function tests, morphological staining of the heart and tests for oxidative stress to evaluate cardiac functional and structural changes. Finally, the expression of Na+/H+ exchanger (NHE1) protein was analyzed by immunohistochemistry and western bolt, and the expression of hairy/enhancer-of-split related with YRPW motif 1 (Hey1) and P-p38 protein was detected by immunofluorescence chemistry and western blotting. The results showed that ACDR can improve cardiac dysfunction, reduce myocardial injury, reduce oxidative stress, and protect the liver in DCM rats. Interestingly, all variations were countered by LiCl. Our study suggests that, along with controlling hyperglycemia, ACDR may improve DCM by reducing NHE1 expression, further inhibiting P-p38 activity and increasing Hey1 expression to reduce oxidative stress.